Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-mutated Solid Tumors
NCT #
NCT06128551
Condition(s)
Solid Tumor
Molecular Target(s)
KRAS
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule
Agents(s)
RMC-6291 and RMC-6236
Phase(s)
I
Mechanism of Action
- RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein
- RMC-6236 is a RASMULTI(ON) inhibitor
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study drugs can be given in combination with an acceptable level of side effects
- The effects of the study drugs (good and bad)
- How much of the study drugs are absorbed into the blood and how fast it is removed
- How the study drugs are acting on your body
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.